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Acehytisine, a multi-ion channel blocker, can markedly inhibit INa, ICa, IKur, If at various concentrations
and effectively terminate and prevent atrial ﬁbrillation (AF) in patients and animal models, but the
molecular mechanism underlying its blockage remains elusive. In this study, we investigated the effects
of acehytisine on action potentials and sodium channels of atrial and ventricular myocytes isolated from
rabbit, using whole-cell recording system. We found that acehytisine exerted stronger blocking effects on
sodium channels in atria than in ventricles, especially at depolarization (IC50: 48.48 ± 7.75 mmol/L in atria
vs. 560.17 ± 63.98 mmol/L in ventricles). It also signiﬁcantly shifted steady state inactivation curves to-
ward negative potentials in atrial myocytes, without affecting the recovery kinetics from inactivation of
sodium channels in the same cells. In addition, acehytisine inhibited INa in a use-dependent manner and
regulated slow inactivation kinetics by different gating conﬁgurations. These ﬁndings indicate that
acehytisine selectively blocks atrial sodium channels and possesses afﬁnity to sodium channel in certain
states, which provides additional evidence for the anti-AF of acehytisine.
© 2016 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).al ﬁbrillation; AP, action po-
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Atrial ﬁbrillation (AF), the most prevalent sustained clinical
arrhythmia, increases morbidity and mortality. Although invasive
electrophysiological procedures have gained signiﬁcant progress in
treating AF, antiarrhythmic drugs (AADs) remain the mainstay for
the management of AF patients. However, the efﬁcacy and/or safety
of AADs are far from ideal. An important limitation of currently
available agents is the risk of inducing severe ventricular arrhyth-
mias and/or organ toxicity. Therefore, it is imperative to develop
more effective and safer anti-AF agents. Currently, administration
of atrial-selective sodium channel blockers has been considered a
novel and effective strategy for the management of AF (1e3).
Several sodium channel blockers (ranolazine, AZD1305, dronedar-
one, Wenxin Keli) have been experimentally demonstrated to
produce atrial-selective electrophysiological effects that allow
them to effectively suppress AF with minimal side effects in the
ventricle (4e9). However, clinical evidence of their effectiveness in
treating AF remains scarce.
Acehytisine (previously named Guanfu base A), a novel diter-
pene alkaloid, is isolated from the root of aconitum coreanumvier B.V. This is an open access article under the CC BY-NC-ND license (http://
X. Fan et al. / Journal of Pharmacological Sciences 132 (2016) 235e243236(Levl.) raipaics, a herbal medication in China for centuries (10). In
both cellular and global electrophysiological studies, acehytisine
has been veriﬁed as a multi-ion channel blocker (sodium channel,
calcium channel, potassium channel, HCN channel (11e17)) which
prevents arrhythmias with low toxicity in animal models (18,19).
Acehytisine, after passing phases II and III clinical studies, has been
approved for the treatment of paroxysmal supraventricular
tachycardia in China in 2005 (20). Currently, it is undergoing phase
IV clinical study. Acehytisine has also been shown to effectively
terminate AF in mongrel dog models induced by vagal stimulation
and topical application of acetylcholine (21,22), but the mecha-
nism of its action has not been elucidated completely. Since ace-
hytisine can effectively terminate superaventricular arrhythmia
but does not induce ventricular arrhythmia concomitantly (20),
we postulate that acehytisine could selectively block sodium
channels in atrium, which may involve suppression and preven-
tion of AF. Therefore, we set out to investigate the electrophysio-
logical characteristics of acehytisine in rabbit atrial myocytes in
this study with the hope to provide novel insights into its anti-AF
mechanisms.2. Materials and methods
2.1. Isolation of cardiomyocytes
Single cardiomyocytes were enzymatically isolated with pro-
cedure as described in the online supplementary methods.2.2. Electrophysiological recording
The INa and action potential recordings were conducted under
voltage and current clamp conﬁguration with the techniques as
described in the online supplementary methods.2.3. Drugs
All reagents used in this study were described in the online
supplementary methods.Table 1
Electrophysiological distinctions between atrial and ventricular myocytes and the effect
Control
Atrium
RMP (mV) 77.71 ± 2.62
Vmax (V/s) CL ¼ 800ms 138.57 ± 6.80
CL ¼ 300ms 131.18 ± 5.18
APD90 (ms) CL ¼ 800ms 216.76 ± 15.83
CL ¼ 300ms 159.30 ± 12.01
Membrane capacitance (pF) 67.69 ± 7.21
Current density Vh ¼ 120 mV 73.75 ± 14.23
(pA/pF) Vh ¼ 90 mV 52.68 ± 11.37
IeV relationship MAX (mV) 38.57 ± 2.43
REV (mV) 25.71 ± 3.45
Activation curve V1/2 (mV) 45.68 ± 0.49
k 6.37 ± 0.46
Inactivation curve V1.2 (mV) 84.64 ± 0.93
k 5.04 ± 0.53
Recovery curve t (ms) 25.18 ± 0.77
Abbreviations: RMP, resting membrane potential; Vmax, maximum upstroke velocity; APD
holding potential; MAX, membrane voltage at maximum current density; REV, reversal
constant. Value are represented as mean ± SD. *P  0.05 and **P  0.01 vs. Atrium; yP 2.4. Data analysis
All results in text, tables and ﬁgures were presented as
means± SD. from ‘n’ experiments. The data acquisition and analysis
were described in the online supplementary methods.3. Results
3.1. Electrophysiological distinctions between atrial and ventricular
myocytes
The transmembrane action potentials (APs) and ion currents
were recorded by patch-clamp technique in atrial and ventricular
myocytes respectively. The electrophysiological distinctions were
showed in Table 1, Figs. 1 and 2. On the one hand, the resting
membrane potential (RMP) was much more depolarized in cells
from atria than that from ventricle (P < 0.01, n ¼ 7 to 7). On the
other, the maximum upstroke velocity (Vmax) was greater and AP
duration at 90% (APD90) of repolarization was longer in ventricular
myocytes than those in atrial ones (P < 0.05, n¼ 7 to 7). In addition,
a smaller membrane capacitance and a greater current density in
atrial were demonstrated than those in ventricular cells while a
greater current density was obtained under hyperpolarization
(90 mV vs. 120 mV) both in atria and ventricle.
In IeV relationship, current density peaked at38.54 ± 2.43mV
in atrial and at 31.42 ± 4.75 mV in ventricular cells, whereas the
reversal potentials were not different. The half-inactivation voltage
(V1/2) in atrial myocytes was more negative (8.76 mV) than that
recorded in ventricular myocytes, whereas the activation curves
remained similar between atria and ventricles. In terms of differ-
ences of recovery curve, the recovery kinetics from inactivation
state were obtained faster in ventricular than atrial myocytes.
These results indicate that a greater percentage of sodium channels
in atria than in ventricles was inactivated at a speciﬁed resting or
take-off potential.3.2. Effects of acehytisine on AP in myocardium
The effects of acehytisine on the AP conﬁguration were shown
in Table 1 and Fig. 1. When a train of relatively slow frequency of
stimulation was applied (cycle length, CL ¼ 800 ms), 10 mmol/Ls of acehytisine on APs and sodium currents.
Achytisine
ventricle Atrium ventricle
88.14 ± 1.77** 75.57 ± 2.07 87.57 ± 2.14
176.91 ± 19.04* 98.75 ± 4.08z 172.67 ± 19.60
183.32 ± 33.76* 69.67 ± 7.77z 175.30 ± 21.41
258.12 ± 40.30* 224.16 ± 29.56 253.57 ± 22.84




31.42 ± 4.75* 39.12 ± 2.51 32.93 ± 3.47
24.28 ± 1.88 24.91 ± 2.46 24.49 ± 2.14
44.64 ± 0.54 40.83 ± 0.55y 44.85 ± 0.63
6.28 ± 0.52 6.53 ± 0.49 6.75 ± 0.41
75.88 ± 0.69** 95.92 ± 0.49z 74.68 ± 0.60
5.81 ± 0.46 5.94 ± 0.38 5.37 ± 0.63
13.97 ± 0.30** 27.01 ± 0.96 16.29 ± 0.88
90, action potential duration at 90% of total repolarization (ms); CL, cycle length; Vh,
potential; V1/2, half-activation or half-inactivation potential; k, slope factor; t, time
0.05 and zP  0.01 vs. Control.
Fig. 1. Myocytes and effects of acehytisine on action potentials in atrial and ventricular
myocytes. (A) Typical morphology of atrial and ventricular myocyte isolated from
rabbit heart. (B) Representative recordings of action potentials were superimposed
before (control), during superfusion of 10 mmol/L acehytisine in atrial and ventricular
myocytes, respectively. (C) The summary data of APD90 in absence and presence of
10 mmol/L acehytisine. yP < 0.01 vs. control.
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n ¼ 7) with slight depolarization of RMP (P > 0.05, n ¼ 7) in
atrial myocytes without changing APD90 in both atria and
ventricle (P > 0.05, n ¼ 7 to 7). When a faster frequency of
stimulation (CL ¼ 300 ms) was applied, acehytisine signiﬁcantly
prolonged APD90 in atrial myocytes (P < 0.01, n ¼ 7) without
changing the Vmax and APD90 (CL ¼ 300 ms) in ventricular
myocytes (P > 0.05, n ¼ 7). Meanwhile, with further shortening
in the interval of pacing, the values of Vmax were more obviously
reduced in atrial myocytes (P < 0.01, n ¼ 7). These results sug-
gest that the atrioventricular difference of AP might result from
atrial-selective effects of acehytisine on various ion channels in
myocardium.
3.3. Atrial-selective blocking effects of sodium channels
The concentration-dependent blockages of sodium channels
by acehytisine were compared between atrial and ventricularmyocytes (Fig. 3A and B). INa was activated at 40 mV from a
holding potential of 120 mV. Firstly, the time-course of the ef-
fects of acehytisine on sodium channels were assessed for a
suitable time point to study drug effects. After control was
recorded, the atrial or ventricular myocytes were superfused with
50 mmol/L acehytisine or vehicle (negative control) and the
voltage steps were applied again every 2 s. Markedly, an early
onset of inhibition by acehytisine in atria than in ventricles, more
rapid and stronger, was observed. The blockage approached a
stable state in 1e4 min after drug application. Current amplitudes
were partially recovered but did not return to the predrug control
level when blank bath solution was washed (n ¼ 4, Fig. 3C). Thus,
all data were collected at 5 min in presence of the drug. Acehy-
tisine inhibited INa expressed in atrial and ventricular myocytes in
a concentration-dependent manner with the average IC50 values
of 193.47 ± 15.70 mmol/L and 845.17 ± 60.96 mmol/L (P < 0.01,
n ¼ 7 to 7), and the Hill coefﬁcients of 0.64 ± 0.16 and 0.67 ± 0.22
(P > 0.05, n ¼ 7 to 7), respectively, suggesting that acehytisine
inhibited INa with a potency that was 4.3-fold greater in atria than
in ventricle. However, membrane potentials of cardiac myocytes,
in normal conditions, hardly shift to hyperpolarization state
(120 mV), under which almost all sodium channels are in pre-
open state. We then investigated the concentration-dependent
blockages of INa in atrial and ventricular myocytes under the
holding potential of 90 mV, near the resting potential. We found
that IC50 calculated from the doseeresponse curves of inhibitory
action was lower in atrial than in ventricular myocytes
(48.48 ± 7.75 mmol/L vs. 560.17 ± 63.98 mmol/L, P < 0.01, n ¼ 7 to
7), but Hill coefﬁcients were not distinct in myocardium
(0.66 ± 0.24 vs. 0.68 ± 0.19, P > 0.05, n ¼ 7 to 7). These results
indicate that acehytisine exerted atrial-dominant blocking
effects on sodium channel, especially under depolarized
condition.3.4. Effects of acehytisine on IeV relationship, activation and
inactivation kinetics of INa
The effects of IeV relationship by acehytisine were illustrated in
Fig. 2G. Compared with control condition, the IeV relationship
(including maximum activated potential and reversal potential)
underwent no major changes. Meanwhile, suppression was similar
at each potential tested in the presence of 50 mmol/L acehytisine
(P > 0.05, n ¼ 7 to 6). The effects of acehytisine on activation and
inactivation kinetics of INa in atrial and ventricular myocytes were
shown in Figs. 4 and 5 and Table 1. After applying 50 mmol/L ace-
hytisine, half-activation voltage of INa was slightly shifted to left
(<5 mV) in atrial cells (P < 0.05, n ¼ 7). In contrast, in ventricular
myocytes, the activation characteristics of INa were not clearly
modiﬁed by acehytisine (P > 0.05, n¼ 7). Similarly, this drug shifted
markedly the inactivation curve by 11.28 mV (P < 0.01, n ¼ 6) in
atrial cells, whereas it was not altered by acehytisine in ventricular
cells (P > 0.05, n ¼ 7).3.5. Effects of acehytisine on recovery kinetics of INa
To determine the rate of recovery of INa from the drug-induced
blockage, a train of double-pulse protocols were employed as
shown in Figs. 4 and 5. In both atrial and ventricular myocytes, the
time courses of INa recovery, expressed by a single exponential
function with a time constant, were not altered in the presence of
50 mmol/L acehytisine (data in Table 1), suggesting that acehytisine
had very rapid unbinding kinetics (rate of dissociation of drug from
the sodium channel).
Fig. 2. Distinctions of kinetics of sodium channels between atrial and ventricular myocytes. Tracings of activation (A), inactivation (B) and recovery(C) currents in atrial and
ventricular myocytes. The normalized steady-state activation (D), inactivation (E) and recovery (F) curves of sodium currents were plotted in atrial and ventricular myocytes. (G) The
currentevoltage relationships of sodium channels in absence and presence of acehytisine.
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The rate-dependent blockage of INa by acehytisine in atrial
myocytes was presented in Fig. 6. In control, the peak amplitude of
INa barely had any changes after 20 repetitive depolarizing pulses at
0.5e4 Hz (n ¼ 5). On the contrary, 10 mmol/L acehytisine (P > 0.05,
n ¼ 6) produced a progressive decline of the INa amplitude by a
1e4 Hz depolarization when the holding potential was clamped
to 90 mV (P < 0.05e0.01, n ¼ 6). The suppression of INa by ace-
hytisine was enhanced along with an increase in the frequency of
stimuli, showing a positive rate-dependent manner. However,
when the holding potential was shifted to hyperpolarization
(120 mV), inhibition of INa was found only at the fastest frequency
of stimuli (4 Hz, P < 0.05, n ¼ 6). In addition, we found that the
amplitudes of sodium currents at the ﬁrst pulse did not decrease
since no marked blocking effect occurred during the diffusion of
10 mmol/L acehytisine at various frequencies. The aforementioned
results suggest that acehytisine inhibited INawithout tonic blocking
effects since it did not bind to sodium channels in the pre-open
(resting) state.3.7. Effects of acehytisine on slow inactivation of INa
To assess the blockage of INa during depolarization, a function of
various durations of depolarization protocol, which can be clariﬁed
to the time course of blocking development by acehytisine, was
applied as shown in Fig. 7. In comparison to control in which cur-
rent amplitude gradually diminished over time and nearly achieved
a plateau after 1 s, INa was speedily decreased by 47% at 1000 ms,
and remained persistently reduced after 1000ms in the presence of
10 mmol/L acehytisine. This phenomenon was more prominent in
the presence of 50 mmol/L acehytisine than in its low concentration.
Meanwhile, the time course of inactivation was ﬁtted to a single
exponential equation with t values of 146.88 ± 55.55 ms (n ¼ 6)
while the time course of inactivation can be simulated ﬁnely by a
double exponential equation both in the presence of 10 and
50 mmol/L acehytisine with two t values (tfast and tslow) repre-
senting the effects of acehytisine on fast and slow inactivation
course of INa respectively. The values of tfast and tslow were
48.50 ± 4.60 ms (vs. control, P < 0.01, n ¼ 6) and 1333.06 ± 35.4 ms
after 10 mmol/L acehytisine administration, and 22.11 ± 1.37 ms (vs.
Fig. 3. Concentration-dependent blockage of acehytisine in atrial and ventricular
myocytes. (A) Original current tracings of sodium channel were superimposed before
(control) and after superfusion of acehytisine in atrial and ventricular myocytes at
holding potentials of 90 mV or 120 mV (B)The concentrationeresponse curve is
plotted based on data from panel A and B, and ﬁtted by the Hill equation. (C) Typical
time course of sodium channels for a vehicle control and for 100 mmol/L acehytisine
washed in and out in atrial and ventricular cells. The current amplitudes were not
decayed signiﬁcantly in the control condition. Arrows represented washout.
X. Fan et al. / Journal of Pharmacological Sciences 132 (2016) 235e243 23910 mmol/L acehytisine, P < 0.01, n ¼ 6) and 1375 ± 10.61 ms (vs.
10 mmol/L acehytisine, P > 0.05, n ¼ 6) after 50 mmol/L acehytisine
administration. These results indicate that acehytisine is an INa
blocker with afﬁnity to multi-state sodium channels and that it
might bind to sodium channels in both open and inactivated states.4. Discussion
Recently, acehytisine has been classiﬁed mainly as a type I AAD
with multi-ion channel blocking effects (11e17). Usingconcentrations comparable to those in clinical trials, we found that
1e500 mmol/L acehytisine signiﬁcantly inhibited atrial INa. Huang
et al. (10) and Yang et al. (23) have determined the plasma con-
centrations of acehytisine (49.98 mg/ml and 14.49 mg/ml) in human.
In this study, we postulate that acehytisine can block sodium
channels in vivo and possesses anti-arrhythmic effects under the
therapeutic concentration. Our work demonstrates that inhibition
of INa by acehytisine was signiﬁcantly larger in atrial myocytes than
in ventricular ones. Meanwhile we also show that atrial sodium
channel had a higher current density than its ventricular counter-
part, which was consistent with previous evidences in canine (5).
The values of IC50 between atria and ventricles clearly differed by
approximately one order of magnitude, especially in depolarized
condition. Similarly, Suzuki et al. have also shown that amiodarone
has stronger inhibitory effects on sodium channels in atria than in
ventricle (IC50: 1.4 ± 0.3 mmol/L in atria vs. 40.4 ± 11.9 mmol/L in
ventricles) (24). It seems that amiodarone is more atrial-selective
than acehytisine. However, simple comparison of our study with
that of Suzuki et al. is not readily justiﬁed because of differences in
experimental conditions, methods, and animals.
To explain the different effects of acehytisine on atrioventricular
sodium channels, we studied the dynamic characteristics of sodium
channels in the presence of acehytisine. The greater depolarization
of RMP in atria than in ventricle often lead to larger fractions of
sodium channels in atria under the state of inactivation than those
in ventricle (2,25). Thus, we investigated the difference of blockage
by acehytisine under various holding potentials. We found that
acehytisine (at low concentration) did not affect sodium channels
from hyperpolarization of membrane potential while it induced the
signiﬁcant suppression of INa in rabbit myocardium when cell
membrane was shifting to positive potentials. This suggests that
acehytisine, like amiodarone (26,27), has low afﬁnity on the resting
state of channel, but can exert state-dependent blockage on sodium
channel. By using a series of protocols to further evaluate the
channel state of drug binding, we found that acehytisine not only
signiﬁcantly shifted steady state inactivation curves toward nega-
tive potentials, but also slightly shifted steady state activation
curves toward positive potentials in atrial myocytes. While the
former suggests that the rate of sodium channel inactivation was
accelerated, the latter indicates that the course of channel opening
was delayed. The changes in activation and inactivation kinetics can
reduce the INa “window current” or “late INa”, which is an important
origin of arrhythmia, systolic dysfunction and cell injury (28). Like
ranolazine, acehytisine also possesses the strong blocking activity
for late INa (29). In addition, INa at the ﬁrst pulse was not reduced in
presence of acehytisine, since no marked blocking effect appeared
during the diffusion drug at various frequencies, suggesting that
acehytisine might interact with the inactivation state or open state
of sodium channel but not the resting state.
To further validate this hypothesis, we also investigated the ef-
fects of acehytisine on slow inactivation of INa. We found that
acehytisine could change the kinetics of both fast and slow inacti-
vation of sodium channels. It speedily decreased the amplitude of
INa at early depolarization and persistently reduced it after late
depolarization, while it affected the control differently, with so-
dium channels being quickly inactivated at early depolarization,
but not continuously blocked while the time courses of depolari-
zation being prolonged. As we know, sodium currents include two
components that possess different gating conﬁgurations. In pres-
ence of acehytisine, sodium channels at different states have
several speciﬁc-afﬁnities to drugs, suggesting that the kinetics of
inactivation differed from that in control. Based on these results, we
conclude that acehytisine can preferentially block open and inac-
tivated sodium channels with the detailed sites binding to sodium
channels being validated by several electropharmological
Fig. 4. Effects of acehytisine on steady-state activation, inactivation and recovery from inactication of INa in atrial myocytes. (AeC) Activation, inactivation and recovery from
inactication of INa of atrial myocytes before and after superfusion of 50 mmol/L acehytisine, respectively. (DeF) The effects of 50 mmol/L acehytisine on steady-state activation,
inactivation and recovery curves of INa in atrial myocytes, respectively.
X. Fan et al. / Journal of Pharmacological Sciences 132 (2016) 235e243240experiments on model cells heterologously expressing mutational
channel proteins.
We also found that acehytisine inhibited INa in a positive rate-
dependent manner, consistent with the results from our
recording AP. The faster the frequency of stimulation, the more
frequently the channels become activated and inactivated in unit
time and the more frequently the channels opened and closed.
Thus, high frequency stimulation increased the probability of
drug binding to the receptor sites of the sodium channel, thereby
reducing sodium channels shifting from the resting state to the
open state. As sodium channels accumulate in the inactivation
state, only a small proportion of sodium channels are left to be
activated. That is, the amount of channel opening time wasreduced in unit time. The more frequently channels open (the
faster the heart rate is), the stronger the blocking effect of ace-
hytisine becomes, a mechanism resembling the effects of rano-
lazine, a preferred drug for atrial tachyarrhythmia treatment. In
addition, acehytisine did not modify the recovery kinetics from
inactivation, indicating that it rapidly dissociated from the so-
dium channel under repolarization, a property recently suggested
to contribute to atrial-selectivity of sodium channel blocker
(2,3,25).
In addition, the results from APs showed that acehytisine
produced the larger descent of Vmax, whose value depends on the
activity of sodium channels, in atrial than in ventricular myo-
cytes, consistent with outcomes from our ion channel recording.
Fig. 5. Effects of acehytisine on steady-state activation, inactivation and recovery from inactication of INa in ventricular myocytes. (AeC) Activation, inactivation and recovery from
inactication of INa of ventricular myocytes before and after superfusion of 50 mmol/L acehytisine, respectively. (DeF) The effects of 50 mmol/L acehytisine on steady-state activation,
inactivation and recovery curves of INa in ventricular myocytes, respectively.
X. Fan et al. / Journal of Pharmacological Sciences 132 (2016) 235e243 241Meanwhile, it did not prolong the duration of AP in ventricular
myocytes, a fact attributable to its little effect on HERG channel
with the exception of the concentration exceeding 1000 mmol/L
(15,17), indicating that acehytisine is a safe AAD with little the
side-effect on QT interval prolongation and TdP. Together with
the inhibition of other ion channels, IKur, HCN currents by ace-
hytisine, atrial APD90 were signiﬁcantly prolonged at fast pacing,
which could enhance blocking effects of sodium channels by
prolongation of the depolarizing time. Comparing to sinus
rhythm, the pharmacological action can be enhanced during fast
atrial rate and long APD under state of AF. Furthermore, it has
been reported that AF, originated from pulmonary vein myocar-
dium (a special type of atrial myocardium) could be effectivelyterminated by sodium channel blocker such as pilsicainide in
experiments and clinical trials (30e32). In all, seeking and
developing atrialeselective sodium channel blockers with high
efﬁciency and low toxicity has been considered as a novel strat-
egy for the anti-AF (1e3).
In summary, the present work suggests that acehytisine exerts
atrial-selective blockage on sodium channels and may have high
afﬁnity to certain states of channels. Like other selective blockers,
acehytisine has rapid kinetics on sodium channels which may
contribute to the substance's anti-AF efﬁcacy and its reduced
proarrhythmic effects at the ventricular level. Therefore, our ﬁnd-
ings are likely to shed important light on the clinical applications of
acehytisine in the treatment of AF.
Fig. 6. Rate-dependent blockage of INa by acehytisine in atrial myocytes. Superimposed tracings of INa obtained from different experiments: in control at 0.5e4 Hz, and in the
presence of 50 mmol/L acehytisine at 0.5e4 Hz, when holding potentials of 90 mV (A) or 120 mV (B) were applied. (C) and (D) The normalized currents of sodium channels were
plotted against each pulse number based on data from panel A and B, respectively.
Fig. 7. Effects of acehytisine on slow inactivation of INa in atrial myocytes. (A) Tracings of INa in atrial myocytes before and after superfusion of 10 or 50 mmol/L acehytisine. The
normalized currents of sodium channels were plotted against various durations of depolarization and ﬁtted by the single or double exponential equation, X axis was expressed by
arithmetic (B) or logarithm (C).
X. Fan et al. / Journal of Pharmacological Sciences 132 (2016) 235e243242
X. Fan et al. / Journal of Pharmacological Sciences 132 (2016) 235e243 243Conﬂict of interest
The authors indicated no potential conﬂicts of interest.
Acknowledgments
We are grateful to Guodong Wang (Jilin Aodong Taonan Phar-
maceu Co., Ltd.) for generously providing acehytisine and Jihua Ma
and Junlian Xing (Wuhan University of Science and Technology) for
the expert technical assistance. We also thank Ms. Na Luo (Center
for Applied English Studies, the University of Hong Kong) for
assistance in writing manuscript.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.jphs.2016.03.014.
References
(1) Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C. Atrial-
selective sodium channel block as a strategy for suppression of atrial ﬁbril-
lation. Ann N Y Acad Sci. 2008;1123:105e112.
(2) Antzelevitch C, Burashnikov A. Atrial-selective sodium channel block as a
novel strategy for the management of atrial ﬁbrillation. J Electrocardiol.
2009;42:543e548.
(3) Burashnikov A, Antzelevitch C. Novel pharmacological targets for the rhythm
control management of atrial ﬁbrillation. Pharmacol Ther. 2011;132:300e313.
(4) Lalevee N, Nargeot J, Barrere-Lemaire S, Gautier P, Richard S. Effects of
amiodarone and dronedarone on voltage-dependent sodium current in hu-
man cardiomyocytes. J Cardiovasc Electrophysiol. 2003;14:885e890.
(5) Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C.
Atrium-selective sodium channel block as a strategy for suppression of atrial
ﬁbrillation: differences in sodium channel inactivation between atria and
ventricles and the role of ranolazine. Circulation. 2007;116:1449e1457.
(6) Kumar K, Nearing BD, Carvas M, Nascimento BC, Acar M, Belardinelli L, et al.
Ranolazine exerts potent effects on atrial electrical properties and abbreviates
atrial ﬁbrillation duration in the intact porcine heart. J Cardiovasc Electro-
physiol. 2009;20:796e802.
(7) Burashnikov A, Sicouri S, Di Diego JM, Belardinelli L, Antzelevitch C. Syner-
gistic effect of the combination of ranolazine and dronedarone to suppress
atrial ﬁbrillation. J Am Coll Cardiol. 2010;56:1216e1224.
(8) Burashnikov A, Zygmunt AC, Di Diego JM, Linhardt G, Carlsson L,
Antzelevitch C. Azd1305 exerts atrial predominant electrophysiological ac-
tions and is effective in suppressing atrial ﬁbrillation and preventing its
reinduction in the dog. J Cardiovasc Pharmacol. 2010;56:80e90.
(9) Burashnikov A, Petroski A, Hu D, Barajas-Martinez H, Antzelevitch C. Atrial-
selective inhibition of sodium-channel current by wenxin keli is effective in
suppressing atrial ﬁbrillation. Heart rhythm. 2012;9:125e131.
(10) Huang Q, Wang GJ, Sun JG, A JY, Zha WB, Zhang Y, et al. Simultaneous
determination of gfa and its active metabolites in human plasma by liquid
chromatography electrospray ionization mass spectrometry and its applica-
tion to pharmacokinetic studies. J Pharm Biomed Anal. 2008;46:728e736.
(11) Wang YP, Chen WZ, Wang XL, Hua Z. Inhibition of guan-fu base a on delayed
rectiﬁer current (ik) in guinea pig ventricular myocytes. Yao xue xue bao.
1996;31:581e584.
(12) Gao X, Pu JL, Yang YM, Wu H, Huang A, Shi SY. Effects of guanfu base a hy-
drochloride on heart l-type calcium channel of rat ventricular myocytes. Chin
J New Drugs. 2006;15:1926e1929.(13) Li Y, Yang YM, Pu JL, Zhu J. Blocking effects of guanfu base a on potassium
current in isolated rat and guinea pig ventricular myocytes. Chin J Card Pacing
Electrophysiol. 2007;20:255e258.
(14) Li Y, Yang YM, Pu JL, Zhu J. Blocking effects of guanfu base a on sodium
channel in isolated guinea pig ventricular myocytes. Chin J Card Arrhyth.
2007;11:47e52.
(15) Huang X, Yang Y, Zhu J, Dai Y, Pu J. The effects of a novel anti-arrhythmic drug,
acehytisine hydrochloride, on the human ether-a-go-go related gene k
channel and its trafﬁcking. Basic Clin Pharmacol Toxicol. 2009;104:145e154.
(16) Fan X, Chen Y, Xing J, Wu P, Chen H, Yang J, et al. Blocking effects of acehy-
tisine on pacemaker currents (i(f)) in sinoatrial node cells and human hcn4
channels expressed in xenopus laevis oocytes. J Ethnopharmacol. 2012;139:
42e51.
(17) Huang X, Yang Y, Zhu J, Xu D, Peng J, Liu J. Comparative effects of guanfu base
a and guanfu base g on herg kþ channel. J Cardiovasc Pharmacol. 2012;59:
77e83.
(18) Liang Y, Zhu J, Yang MY, Li JD, Sun Y, Guan J. Hemodynamic effects of ace-
hytisine on wuzhishan micropig with acute coronary ischemic. Chin J New
Drugs Clin Rem. 2006;26:190e195.
(19) Liang Y, Zhu J, Yang YM, Li JD, Sun Y, Guan J, et al. Electrophysiological effects
of acehytisine hydrochloride in a porcine model of acute coronary occlusion.
Zhonghua xin xue guan bing za zhi. 2006;34:1035e1039.
(20) Gao X, Zhu J, Yang YM, Li JD, Yang ZM, Liu JH, et al. Efﬁcacy of intravenous
acehytisine hydrochloride versus propafenone on terminating paroxysmal
supraventricular tachycardia: a double-blinded, randomized multi-center
study. Zhonghua xin xue guan bing za zhi. 2007;35:151e154.
(21) Dong YL, Chen WZ. Effects of guan-fu base a on experimental cardiac ar-
rhythmias and myocardial contractility. Yao xue xue bao. 1995;30:577e582.
(22) Wang M, Zhu J, Yang YM, Li CR, Tian Y, Chen XS. Effects of acehytisine hy-
drochloride on vagotonic atrial ﬁbrillation in mongrel dogs. Chin J Card Pacing
Electrophysiol. 2008;22:148e152.
(23) Yang X, Wang G, Ling S, Qiu N, Wang G, Zhu J, et al. Determination of guan-fu
base a, a new anti-arrhythmic, in human plasma by gas chromatography and
electron-capture detection. J Chromatogr B Biomed Sci Appl. 2000;740:
273e279.
(24) Suzuki T, Morishima M, Kato S, Ueda N, Honjo H, Kamiya K. Atrial selectivity in
naþchannel blockade by acute amiodarone. Cardiovasc Res. 2013;98:
136e144.
(25) Antzelevitch C, Burashnikov A. Atrial-selective sodium channel block as a
novel strategy for the management of atrial ﬁbrillation. Ann N Y Acad Sci.
2010;1188:78e86.
(26) Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone.
Cardiovasc Res. 1997;35:13e29.
(27) Zimetbaum P. Amiodarone for atrial ﬁbrillation. N Engl J Med. 2007;356:
935e941.
(28) Wang XJ, Wang LL, Fu C, Zhang PH, Wu Y, Ma JH. Ranolazine attenuates the
enhanced reverse na(þ)-ca(2)(þ) exchange current via inhibiting hypoxia-
increased late sodium current in ventricular myocytes. J Pharmacol Sci.
2014;124:365e373.
(29) Jin SS, Guo Q, Xu J, Yu P, Liu JH, Tang YQ. Antiarrhythmic ionic mechanism of
guanfu base aeselective inhibition of late sodium current in isolated ven-
tricular myocytes from guinea pigs. Chin J Nat Med. 2015;13:361e367.
(30) Takahara A, Hagiwara M, Namekata I, Tanaka H. Pulmonary vein myocardium
as a possible pharmacological target for the treatment of atrial ﬁbrillation.
J Pharmacol Sci. 2014;126:1e7.
(31) Takahara A, Sugimoto T, Kitamura T, Takeda K, Tsuneoka Y, Namekata I, et al.
Electrophysiological and pharmacological characteristics of triggered activity
elicited in guinea-pig pulmonary vein myocardium. J Pharmacol Sci.
2011;115:176e181.
(32) Takahara A, Takeda K, Tsuneoka Y, Hagiwara M, Namekata I, Tanaka H.
Electrophysiological effects of the class ic antiarrhythmic drug pilsicainide on
the guinea-pig pulmonary vein myocardium. J Pharmacol Sci. 2012;118:
506e511.
